Article info

Protocol
Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol

Authors

  1. Correspondence to Dr Liang Peng; pliang{at}mail.sysu.edu.cn; Professor Xuejun Li; lixuejun{at}mail.sysu.edu.cn; Professor Jianguo Li; ljiang{at}mail.sysu.edu.cn
View Full Text

Citation

Zhu S, Wu L, Mei Y, et al
Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol

Publication history

  • Received January 16, 2021
  • Accepted September 27, 2021
  • First published October 25, 2021.
Online issue publication 
October 25, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.